203 related articles for article (PubMed ID: 10697116)
21. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.
Mizuguchi H; Kay MA
Hum Gene Ther; 1999 Aug; 10(12):2013-7. PubMed ID: 10466635
[TBL] [Abstract][Full Text] [Related]
22. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.
Brough DE; Lizonova A; Hsu C; Kulesa VA; Kovesdi I
J Virol; 1996 Sep; 70(9):6497-501. PubMed ID: 8709289
[TBL] [Abstract][Full Text] [Related]
23. Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.
Thomas MA; Song R; Demberg T; Vargas-Inchaustegui DA; Venzon D; Robert-Guroff M
PLoS One; 2013; 8(10):e76344. PubMed ID: 24143187
[TBL] [Abstract][Full Text] [Related]
24. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung.
Kaplan JM; Armentano D; Sparer TE; Wynn SG; Peterson PA; Wadsworth SC; Couture KK; Pennington SE; St George JA; Gooding LR; Smith AE
Hum Gene Ther; 1997 Jan; 8(1):45-56. PubMed ID: 8989994
[TBL] [Abstract][Full Text] [Related]
25. Differential influence of the E4 adenoviral genes on viral and cellular promoters.
Grave L; Dreyer D; Dieterle A; Leroy P; Michou AI; Doderer C; Pavirani A; Lusky M; Mehtali M
J Gene Med; 2000; 2(6):433-43. PubMed ID: 11199264
[TBL] [Abstract][Full Text] [Related]
26. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
27. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
28. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.
Krougliak V; Graham FL
Hum Gene Ther; 1995 Dec; 6(12):1575-86. PubMed ID: 8664382
[TBL] [Abstract][Full Text] [Related]
29. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
[TBL] [Abstract][Full Text] [Related]
30. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions.
Wang Q; Jia XC; Finer MH
Gene Ther; 1995 Dec; 2(10):775-83. PubMed ID: 8750018
[TBL] [Abstract][Full Text] [Related]
31. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
32. Improved adenoviral vector for vascular gene therapy : beneficial effects on vascular function and inflammation.
Qian HS; Channon K; Neplioueva V; Wang Q; Finer M; Tsui L; George SE; McArthur J
Circ Res; 2001 May; 88(9):911-7. PubMed ID: 11349000
[TBL] [Abstract][Full Text] [Related]
33. Impact of the adenoviral E4 Orf3 protein on the activity and posttranslational modification of p53.
DeHart CJ; Perlman DH; Flint SJ
J Virol; 2015 Mar; 89(6):3209-20. PubMed ID: 25568206
[TBL] [Abstract][Full Text] [Related]
34. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
[TBL] [Abstract][Full Text] [Related]
35. Constitutive expression of the adenovirus E3-14.7K protein does not prolong adenovirus vector DNA persistence but protects mice against lipopolysaccharide-induced acute hepatitis.
Gantzer M; Spitz E; Accard N; Rooke R
Hum Gene Ther; 2002 May; 13(8):921-33. PubMed ID: 12031125
[TBL] [Abstract][Full Text] [Related]
36. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.
Yeh P; Dedieu JF; Orsini C; Vigne E; Denefle P; Perricaudet M
J Virol; 1996 Jan; 70(1):559-65. PubMed ID: 8523570
[TBL] [Abstract][Full Text] [Related]
37. Adenoviral vector expressing ICP47 inhibits adenovirus-specific cytotoxic T lymphocytes in nonhuman primates.
Scaria A; Sullivan JA; St George JA; Kaplan JM; Lukason MJ; Morris JE; Plog M; Nicolette C; Gregory RJ; Wadsworth SC
Mol Ther; 2000 Nov; 2(5):505-14. PubMed ID: 11082324
[TBL] [Abstract][Full Text] [Related]
38. Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.
Pham L; Nakamura T; Gabriela Rosales A; Carlson SK; Bailey KR; Peng KW; Russell SJ
J Gene Med; 2009 Mar; 11(3):197-206. PubMed ID: 19140107
[TBL] [Abstract][Full Text] [Related]
39. Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products.
Gilbert R; Nalbantoglu J; Howell JM; Davies L; Fletcher S; Amalfitano A; Petrof BJ; Kamen A; Massie B; Karpati G
Hum Gene Ther; 2001 Sep; 12(14):1741-55. PubMed ID: 11560768
[TBL] [Abstract][Full Text] [Related]
40. Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms.
Medghalchi S; Padmanabhan R; Ketner G
Virology; 1997 Sep; 236(1):8-17. PubMed ID: 9299612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
